Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

Abstract

Replication-selective microbial agents hold promise as a novel cancer treatment platform. dl1520 (Onyx-015), an E1B-55 kD gene-deleted adenovirus, was the first such genetically engineered agent to be tested in humans. Over 200 cancer patients have been treated to date on over 10 clinical trials (phases I-III). The virus was generally well-tolerated at doses of up to 2 × 1012 particles by intratumoral, intraperitoneal, hepatic arterial and intravenous administration; no maximally tolerated doses were identified by any route of administration. Viral replication was tumor-selective, and was documented after administration by all routes; replication was generally transient (<10 days), however, and was variable depending on tumor histology. single agent efficacy has been limited to date (0–14% local tumor regression rates). in combination with chemotherapy, however, encouraging antitumoral activity has been demonstrated. these clinical research results demonstrate the potential of this novel treatment platform, as well as the hurdles to be overcome. novel replication-selective agents with improved potency are needed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Merritt J et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer Cancer Gene Ther 1997 4: S12 (Abstr.)

    Google Scholar 

  2. Nemunaitis J et al. Three phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (AdCMV-p53) in patients with recurrent/refractory head and neck cancer Proc Am Soc Clin Oncol 1999 18: 1661

    Google Scholar 

  3. Kirn D . Replication-selective micro-organisms: fighting cancer with targeted germ warfare J Clin Invest 2000 105: 836–838

    Article  Google Scholar 

  4. Heise C, Kirn D . Replication-selective adenviruses as oncolytic agents J Clin Invest 2000 105: 847–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pawelek J, Low K, Bermudes D . Tumor-targeted Salmonella as a novel anticancer vector Cancer Res 1997 57: 4537–4544

    CAS  PubMed  Google Scholar 

  6. Heise C et al. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628

    CAS  PubMed  Google Scholar 

  7. Kirn D . Selectively-replicating viruses as therapeutic agents against cancer. In: Gerschenson LA (ed.) Cancer Gene Therapy Vol. 1: Academic Press: San Diego 1998 pp 235–248

    Google Scholar 

  8. Smith R et al. Studies on the use of viruses in the treatment of carcinoma of the cervix Cancer 1956 9: 1211–1218

    Article  PubMed  Google Scholar 

  9. Webb HE, Smith CE . Viruses in the treatment of cancer Lancet 1970 1: 1206–1208

    Article  CAS  PubMed  Google Scholar 

  10. Asada T . Treatment of human cancer with mumps virus Cancer 1974 34: 1907–1928

    Article  CAS  PubMed  Google Scholar 

  11. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856

    Article  CAS  PubMed  Google Scholar 

  12. Mineta T, Rabkin SD, Martuza RL . Treatment of malignantgliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant Cancer Res 1994 54: 3963–3966

    CAS  PubMed  Google Scholar 

  13. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943

    Article  CAS  PubMed  Google Scholar 

  14. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells (see comments) Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  15. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments) Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  16. Lorence RM et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy Cancer Res 1994 54: 6017–6021

    CAS  PubMed  Google Scholar 

  17. Van Pachterbeke C et al. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures Int J Cancer 1993 55: 672–677

    Article  CAS  PubMed  Google Scholar 

  18. Coffey M, Strong J, Forsyth P, Lee P . Reovirus therapy of tumors with activated ras pathway Science 1998 282: 1332–1334

    Article  CAS  PubMed  Google Scholar 

  19. Mastrangelo M, Eisenlohr L, Gomella L, Lattime E . Poxvirus vectors: orphaned and underappreciated J Clin Invest 2000 105: 1031–1034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gromeier M et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma (see comments) Proc Natl Acad Sci USA 2000 97: 6803–6808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Stojdl DF et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 2000 6: 821–825

    Article  CAS  PubMed  Google Scholar 

  22. Wold WS, Hermiston TW, Tollefson AE . Adenovirus proteins that subvert host defenses Trends Microbiol 1994 2: 437–443

    Article  CAS  PubMed  Google Scholar 

  23. Sparer TE et al. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model J Virol 1996 70: 2431–2439

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 1997 57: 2559–2563

    CAS  PubMed  Google Scholar 

  25. Heise C, Williams A, Olesch J, Kirn D . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects Cancer Gene Ther 1999 6: 499–504

    Article  CAS  PubMed  Google Scholar 

  26. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856

    Article  CAS  PubMed  Google Scholar 

  27. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943

    Article  CAS  PubMed  Google Scholar 

  28. Ganly I, Soutar D, Brown R, Kaye S . p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br Cancer 2000 82: 392–398

    Article  CAS  Google Scholar 

  29. Scheffner M, Munger K, Byrne JC, Howley PM . The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc Natl Acad Sci USA 1991 88: 5523–5527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers Science 1991 253: 49–53

    Article  CAS  PubMed  Google Scholar 

  31. Harada J, Berk A . p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication J Virol 1999 73: 5333–5344

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Reid T et al. Hepatic arterial infusion of a replication-selective adenovirus, Onyx-015: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 953 (Abstr.)

    Google Scholar 

  33. Kemeny N et al. Hepatic arterial infusion of chemotherapy following resection of hepatic metastases from colorectal cancer N Engl J Med 1999 341: 2039–2048

    Article  CAS  PubMed  Google Scholar 

  34. Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806

    CAS  PubMed  Google Scholar 

  35. Hecht JR et al. A phase I study of multiple direct injections of ONYX-015 adenovirus under endoscopic ultrasound guidance Proc Am Soc Clin Oncol 1999 18: 186 (Abstr.)

    Google Scholar 

  36. Hecht R et al. Endoscopic ultrasound-guided intratumoral injection of pancreatic carcinomas with a replication-selective adenovirus: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 1039 (Abstr.)

    Google Scholar 

  37. Kirn DH et al. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Proc Am Soc Clin Oncol 1999 18: 1505 (Abstr.)

    Google Scholar 

  38. Vasey P et al. A phase I trial of an E1B-55kD gene-deleted adenovirus administered by intraperitoneal injection into patients with advanced, refractory ovarian carcinoma Proc Am Soc Clin Oncol 2000 19: 1512 (Abstr.)

    Google Scholar 

  39. Nemunaitis J, Cunningham C, Randlev B, Kirn D . A phase I trial of intravenous administration with a replication-selective adenovirus, dl 1520 Proc Am Soc Clin Oncol 2000 19: 724 (Abstr.)

    Google Scholar 

  40. Khuri F et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885

    Article  CAS  PubMed  Google Scholar 

  41. Reid A et al. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma EORTC-NCI-AACR Meeting on Molecular Therapeutics of Cancer 1999

    Google Scholar 

  42. Kirn D et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer Proc Am Soc Clin Oncol 1998 17: 391a

    Google Scholar 

  43. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments) Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  44. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (see comments) Nat Med 2000 6: 879–885

    Article  CAS  PubMed  Google Scholar 

  45. Goodrum FD, Ornelles DA . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 1998 72: 9479–9490

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Rothmann T et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells J Virol 1998 72: 9470–9478

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Dobner T, Horikoshi N, Rubenwolf S, Shenk T . Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor Science 1996 272: 1470–1473

    Article  CAS  PubMed  Google Scholar 

  48. Yew PR, Liu X, Berk AJ . Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53 Genes Dev 1994 8: 190–202

    Article  CAS  PubMed  Google Scholar 

  49. Goodrum FD, Ornelles DA . The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle J Virol 1997 71: 548–561

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Heise C et al. An E1A mutant adenovirus with potent and selective systemic antitumoral efficacy Nat Med 2000 6: 1134–1139

    Article  CAS  PubMed  Google Scholar 

  51. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121

    Article  CAS  PubMed  Google Scholar 

  52. Dobbelstein M et al. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence EMBO J 1997 16: 4276–4284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Gooding LR . Regulation of TNF-mediated cell death and inflammation by human adenoviruses Infect Agents Dis 1994 3: 106–115

    CAS  PubMed  Google Scholar 

  54. Kirn D et al. Adenovirus E1A CR2 mutants as selectively-replicating agents for cancer Cancer Gene Ther 1998

  55. Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 2000 19: 2–12

    Article  CAS  PubMed  Google Scholar 

  56. Hawkins L et al. Replicating adenoviral gene therapy Proc Am Assoc Cancer Res 1999 40: 476 (Abstr.)

    Google Scholar 

  57. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy (see comments) Hum Gene Ther 1998 9: 1323–1333

    Article  CAS  PubMed  Google Scholar 

  58. Wildner O, Blaese RM, Morris JM . Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase Cancer Res 1999 59: 410–413

    CAS  PubMed  Google Scholar 

  59. Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene Cancer Res 1994 54: 5745–5751

    CAS  PubMed  Google Scholar 

  60. Roelvink P et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571

    Article  CAS  PubMed  Google Scholar 

  61. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ . In situ cytokine gene transfection using vaccinia virus vectors Semin Oncol 1996 23: 88–100

    CAS  PubMed  Google Scholar 

  62. Low K et al. Lipid A mutant salmonella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo Nat Biotechnol 1999 17: 37–41

    Article  CAS  PubMed  Google Scholar 

  63. Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with head and neck cancer Cancer Res 2000 60: 6359–6366

    CAS  PubMed  Google Scholar 

  64. Heisse C, Kirn D . Combination therapy with a replication-selective adenovirus and cisplatin chemotherapy; dependence on sequencing but independence from p53 gene status or route of administration Clin Cancer Res (in press)

  65. Ries S et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (Onyx-015) Nature Med 2000 6: 1128–1133

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The following individuals have been instrumental in making this manuscript possible: John Nemunaitis, Stan Kaye, Tony Reid, Fadlo Khuri, James Abruzzesse, Eva Galanis, Joseph Rubin, Antonio Grillo-Lopez, Carla Heise, Larry Romel, Chris Maack, Sherry Toney, Nick LeMoine, Britta Randlev, Patrick Trown, Fran Kahane and Margaret Uprichard.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirn, D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 8, 89–98 (2001). https://doi.org/10.1038/sj.gt.3301377

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301377

Keywords

This article is cited by

Search

Quick links